熱門資訊> 正文
安妮卡与卡利根合作伙伴签署合作协议,宣布回购
2024-05-29 04:35
- Anika Therapeutics (NASDAQ:ANIK) entered into a cooperation agreement with Caligan Partners LP.
- As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the company’s Board of Directors, effective immediately.
- In addition, the Anika Board of Directors has authorized a $40M share repurchase program, $15M of which will be effected through a 10b5-1 plan to be completed by June 30, 2025, and the remainder of which will be purchased in the open market through June 30, 2026.
- This new buyback authorization replaces the company’s share repurchase program announced in April 2023.
- The Anika Board will temporarily expand to ten directors until the retirement of current Anika director Jeffery Thompson is effective at the 2024 Annual Meeting of Stockholders.
- Under the terms of the cooperation agreement, Caligan has agreed to support the Board’s full slate of directors at the 2024 Annual Meeting.
- Source: Press Release
More on Anika Therapeutics
- Anika Therapeutics, Inc. (ANIK) Q1 2024 Earnings Call Transcript
- Anika Therapeutics, Inc. 2024 Q1 - Results - Earnings Call Presentation
- Anika Therapeutics, Inc. (ANIK) Q4 2023 Earnings Call Transcript
- Anika Therapeutics Q1 2024 Earnings Preview
- Anika Therapeutics Non-GAAP EPS of $0.05 beats by $0.28, revenue of $42.97M beats by $1.57M
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。